NewAmsterdam Pharma’s drug reduced cholesterol in patients with a genetic disorder by 41% at Week 52, confirming the therapy’s efficacy but falling outside of the range shown in a previous study. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results